Recombinant LAL alternatives by Hyglos - Endpoint Fluorescent Assays

True Innovation with Phage recombinant Technology and recombinant Horseshoe Crab Factor C

Highly specific and robust detection of endotoxin (LPS) helps you make confident in process control (IPC) and product release decisions:

  • Selecting the ideal endotoxin (LPS) test method for your samples
  • Removing inhibitory effects due to buffer and sample components
  • Improving reproducibility of results
  • Optimizing endotoxin recovery

Assays:

Endpoint fluorescence microplate assay based on recombinant Factor C (rFC), without solid phase, for the quantitative determination of endotoxins (lipopolysaccharides) in non-critical matrices such as process water and environmental samples. EndoZyme® offers excellent LPS-specificity, a very high test sensitivity (0.005 EU/ml) as well as a broad measurement range (0-50 EU/ml). Characterized by an excellent lot-to-lot consistency.

[Click here for EndoZyme® product & ordering information]

Endpoint fluorescence microplate assay with solid phase using a phage-derived capture molecule for the quantitative binding and determination of endotoxins (lipopolysaccharides). The world's first endotoxin detection system based on ELISA-technology overcoming limitations of traditional methods, such as the LAL (Limulus amebocyte lysate). A highly robust method with unprecedented salt and detergent tolerance. Developed and intended for complex sample matrices such as biopharmaceuticals; proteins, antibodies and vaccines.

[Click here for EndoLISA® product & ordering information]